drugset

drugset / Trial / NCT01060566

Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

NCT01060566 ↗

Phase 1 Completed 24 enrolled Vertex Pharmaceuticals Incorporated

Non-randomizedCrossoverOpen-labelTreatment

Summary

The objectives of this study are to evaluate the effects of VX-770 on Midazolam and Rosiglitazone, and the effect of Fluconazole on VX-770.

Timeline

Start: 2010-02
Primary completion: 2010-03
Completion: 2010-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivacaftor	Other / unclassified	150 mg	Oral

Indications